Comparative Pharmacology
Head-to-head clinical analysis: ADRENALIN versus EPIPEN JR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADRENALIN versus EPIPEN JR.
ADRENALIN vs EPIPEN JR.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Direct-acting sympathomimetic amine that acts on alpha- and beta-adrenergic receptors. Alpha-1 activation causes vasoconstriction, beta-1 activation increases heart rate and contractility, beta-2 activation causes bronchodilation.
Epinephrine is a direct-acting sympathomimetic amine that acts on alpha- and beta-adrenergic receptors. Alpha-adrenergic effects include vasoconstriction, which reduces edema and increases blood pressure. Beta-adrenergic effects include bronchodilation, positive inotropic and chronotropic cardiac effects, and inhibition of histamine release from mast cells.
1 mg (1 mL of 1:1000 solution) intramuscularly or subcutaneously every 5-20 minutes as needed; for cardiac arrest: 1 mg intravenously or intraosseously every 3-5 minutes.
Epinephrine 0.3 mg intramuscularly in the mid-outer thigh every 5-15 minutes as needed for anaphylaxis.
None Documented
None Documented
Approximately 2-3 minutes for the parent drug in plasma; clinical effects are short-lived due to rapid uptake and metabolism. In severe shock or hepatic impairment, half-life may be slightly prolonged.
Terminal elimination half-life is approximately 2-3 minutes following intravenous administration. Clinically, the short half-life necessitates repeat dosing or continuous infusion for sustained effect. After intramuscular injection, absorption is slower, and the effective half-life is longer due to continued absorption.
Primarily metabolized in the liver and other tissues by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). Renal excretion of metabolites (metanephrine, vanillylmandelic acid) and unchanged drug (<2% as unchanged). Biliary/fecal excretion is minimal (<5%).
Epinephrine is rapidly metabolized in the liver and other tissues by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). The metabolites, including metanephrine and vanillylmandelic acid (VMA), are primarily excreted renally. About 85-90% of an administered dose is eliminated in the urine within 24 hours, with less than 5% excreted unchanged. Biliary/fecal excretion is minimal (<5%).
Category C
Category C
Adrenergic Agonist
Adrenergic Agonist